The role of interim-foscarnet prophylaxis in preventing cytomegalovirus infection after ex vivo αβ T cell-depleted haploidentical hematopoietic cell transplant in children

Bone Marrow Transplant. 2021 Feb;56(2):505-507. doi: 10.1038/s41409-020-01020-z. Epub 2020 Aug 8.

Authors

Affiliations

¹ Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
² Department of Pediatrics, Chungnam National University Hospital, Daejon, Korea.
³ Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
⁴ Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. hojim@amc.seoul.kr.

PMID: 32772046
DOI: 10.1038/s41409-020-01020-z

No abstract available

Publication types

Letter

MeSH terms

Antiviral Agents / therapeutic use
Child
Cytomegalovirus Infections* / drug therapy
Cytomegalovirus Infections* / prevention & control
Foscarnet / therapeutic use
Hematopoietic Stem Cell Transplantation*
Humans
T-Lymphocytes
Transplantation, Haploidentical

Substances

Antiviral Agents
Foscarnet